DUBLIN, October 27, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Genome Editing Global Market-Forecast to 2022" report to their offering.

The genome editing global market over the forecast period 2015 to 2022 and the market is expected to grow at a CAGR of 31.1%.

The Genome editing global market is segmented based on technology, applications, products, end users and geography. Technologies segment consists of Zinc Finger Nucleases (ZFN), Transcriptor-activator-like effector nuclease (TALEN); Clustered regularly interspaced short palindromic repeats (CRISPR) and other gene modification techniques such as Recombinant adeno-associated virus (rAAV), piggyBac transposon, megatales etc.

Applications identified includes, basic research, agriculture biotechnology, animal research, drug discovery and development. Products are classified into reagents, enzymes and consumables, instruments, cell lines & animal models and software.  Depending on the end users, the genome editing global market is sectioned into academic & government institutions, pharmaceutical & biotechnology companies, plant biotechnology and others.

 Increased R&D expenditure and growth of biotechnology and pharmaceutical industries, increasing private and public sector funding, rapid advancements in sequencing and gene editing technologies, non-labeling of gene-edited products as Genetically Modified Organisms (GMOs), applications in various drug discovery processes are some of the factors driving the genome editing global market growth. Factors such as stringent regulatory framework, ethical issues concerning editing human embryo and adverse public perception, unavailability of gene-editing based therapeutics in the market, off-target effects of CRISPR and patent disputes associated with CRISPR technology are hampering the market growth.

The genome editing global market is a consolidated market with key players such as Applied Stemcell (U.S.), Cellectis S.A. (France), Genscript (U.S.), Horizon Discovery Group (U.K.), Merck KGaA (Germany), Origene Technologies (U.S.), Sangamo Biosciences (U.S.), System Biosciences (U.S.), Thermo Fisher Scientific (U,S,), Transposagen (U.S.).

Key Topics Covered:

1 Executive Summary

2 Introduction

2.1 Key Takeaways
2.2 Report Description
2.3 Markets Covered
2.4 Stakeholders
2.5 Research Methodology

3 Market Overview

3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.4 Market Dynamics
3.4.1 Drivers And Opportunities
3.4.1.1 Increased R&D Expenditure And GROWth Of Biotechnology And Pharmaceutical Industries.
3.4.1.2 Investments From Both Public And Private Sectors For Gene-Editing Technology
3.4.1.3 Technological Advancements In Sequencing And Gene Editing Technologies
3.4.1.4 Non-Transgenic Breeding Technologies And Gene-Edited Plants Not Labelled As Gmo In Many Countries
3.4.1.5 Improvement In Drug Discovery Process
3.4.1.6 Varied Applications In Drug Discovery And Development, Plant Engineering, Improvement In Animal Traits, Therapeutics
3.4.1.7 Precision Medicine And New Therapeutics For Genetic And Other Disorders
3.4.2 Restraints And Threats
3.4.2.1 Stringent Regulatory Frameworks
3.4.2.2 Ethical Issues Concerning Editing Human Embryo And Adverse Public Perception
3.4.2.3 Unavailability Of Gene-Editing Based Therapeutic Product In The Market And Less Geographic Penetration Due To Uncertain Regulations
3.4.2.4 Patent Dispute Associated With Crispr/Cas
3.4.2.5 Off-Target Effects Of Crispr/Cas9 Genome Editing Technology
3.5 Porter's Five Force Analysis
3.6 Regulatory Affairs
3.7 Patent Analysis
3.8 Funding Scenario
3.9 Collaboration, Joint Venture, Partnership, Agreement
3.1 Market Share Analysis

4 Genome Editing Global Market, By Technology

4.1 Introduction
4.2 Zinc Finger Nuclease (Zfn)
4.3 Transcription Activator-Like Effector Nucleases (Talen)
4.4 Clustered Regularly Interspaced Short Palindromic Repeats (Crispr/Cas9)
4.4.1 Wt Crispr/Cas9
4.4.2 Crispr/Cas9 Nickase
4.4.3 Crispr Dcas9
4.5 Others
4.5.1 Recombinant Adeno-Associated Virus (R Aav)
4.5.2 Piggybac Transposase And Sleeping Beauty Transposon
4.5.3 Arcus (Homing Endonuclease) And Megatal
4.5.4 Targatt And Rapid Trait Development System (Rtds)

5 Genome Editing Global Market, By Application

5.1 Introduction
5.2 Basic Research
5.2.1 Transcription Activation/Repression
5.2.2 Genomic Screening
5.2.3 Genomic Visualization
5.3 Plant Biotechnology/Agriculture
5.4 Animal Biotechnology
5.4.1 Animal Health
5.4.2 Livestock
5.4.3 Other
5.5 Drug Discovery And Development
5.5.1 Pre-Clinical
5.5.2 Clinical

6 Genome Editing Global Market, By Products And Services

6.1 Introduction
6.2 Reagents, Enzymes And Consumables
6.2.1 Genome Editing Tools And Kits
6.2.2 Delivery Tools
6.2.3 Other Reagents, Enzymes And Consumables
6.3 Cell Lines And Animal Models
6.4 Genome Editing Services
6.5 Instruments
6.6 Software

7 Genome Editing Global Market, By End Users

7.1 Introduction
7.2 Academic And Government Research Institutes
7.3 Plant Biotechnology Companies
7.4 Pharmaceutical And Biotechnology Companies
7.5 Others
7.5.1 Animal Biotechnology
7.5.2 Contract Research Organizations (Cro)

8 Genome Editing Global Market, By Region

9 Competitive Landscape

9.1 Introduction
9.1.1 Licensing Agreement And Others As A Major GROWth Strategy Of Market Players
9.2 Licensing Agreement
9.3 Other Developments
9.4 Agreement/Collaboration/Partnership/Joint Venture
9.5 Approval
9.6 New Product Launch
9.7 Acquisitions

10 Major Companies

- Abcam
- Addgene
- Agilent Technologies
- Applied Biological Materials (Abm)
- Axol Bioscience Ltd
- Bio-Rad Laboratories
- Caribou Biosciences
- Charles River Laboratories
- Cibus
- Crispr Therapeutics
- Desktop Genetics
- Discovery Genomics
- Editas Medicine
- Eisai
- Ers Genomics
- GE Healthcare
- Genecopoeia
- Genus Inc
- Homology Medicines
- Illumina
- Integrated Dna Technologies (Idt)
- Intellia Therapeutics
- Lonza
- New England Biolabs (Neb)
- Pacific Bioscience
- Precision Biosciences
- Proteonic B.V.
- Recombinetics
- Shire Plc
- Stemgent, Inc
- Syngenta
- Takara Bio
- Targetgene Biotechnologies
- Tide
- Toolgen
- Transgenic
- Viravecs Labs

For more information about this report visit http://www.researchandmarkets.com/research/5cf622/genome_editing

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets